key: cord-0924935-m3i5314b
authors: Bertaglia, Valentina; Reale, Maria Lucia; Bironzo, Paolo; Palesandro, Erica; Mariniello, Annapaola; Leone, Gianmarco; Tabbò, Fabrizio; Bungaro, Maristella; Audisio, Marco; Rapetti, Simonetta; Di Stefano, Rosario Francesco; Carnio, Simona; Artusio, Elisa; Capelletto, Enrica; Sperone, Paola; Passiglia, Francesco; Novello, Silvia
title: Italian Survey on the clinical management of non-small cell lung cancer patients during the COVID-19 pandemic: a lesson for the second wave
date: 2020-11-27
journal: Crit Rev Oncol Hematol
DOI: 10.1016/j.critrevonc.2020.103189
sha: c1a6898d3e92b83bf6dd569521713845a1048a38
doc_id: 924935
cord_uid: m3i5314b

This study investigated the clinical management of non small cell lung cancer (NSCLC) patients during the first wave of coronavirus disease 2019 (COVID-19) outbreak in Italy. A 29-questions survey was sent to 95 Italian thoracic oncologists, with 77% of them declaring significant changes in the outpatients management and treatment. The results of this survey pointed out a significant delay of lung cancer diagnosis along with a relevant reduction of patients’ accrual within clinical trials, while telemedicine emerged as a valid support for patient-healthcare interactions. Therapeutic indications followed the guidelines for adjuvant chemotherapy and concurrent chemo-radiation. Clinical indications to first-line therapies were largely confirmed, while major changes regarded the selection of second line treatment options as well as the management of elderly population. This work may represent a valid source of information to improve the clinical management of NSCLC patients during second wave of COVID-19 pandemic.

4. Discussion

At the end of 2019, a novel viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was reported at Wuhan, China (Guan et al., 2020) . Since then, the related coronavirus disease 2019 (COVID-19) syndrome, has progressively involved countries outside China leading the World Health Organization (WHO) to declare the state of pandemic on 11 th March 2020. Since the initial detection of the virus, more than 48 million cases and more than 1.200.000 deaths from COVID-19 have been confirmed worldwide (WHO website, 2020). Italy has been one of the most affected countries with, as of 7 th November 2020, 809.000 confirmed COVID-19 cases and 48.000 deaths, according to the National Institute of Health (ISS,'Istituto Superiore di Sanità) data (ISS website, 2020).

In this challenging situation, the oncological community was called to protect cancer patients, considered one of the most vulnerable population, due to coexisting chronic diseases, overall poor health status, type of infection and systemic immunosuppressive condition caused by both cancer and anticancer therapies (Kuderer et al., 2020) . In this regard, the Italian Association of Medical Oncology (AIOM) has proposed specific J o u r n a l P r e -p r o o f recommendations to optimize the clinical management of patients and to regulate the access of both patients and caregivers to the hospitals, in order to encourage a careful evaluation of risk/benefit ratio case by case and, ultimately, minimize the risk of infection (AIOM website). Accumulating evidence suggest that lung cancer patients are more susceptible to infection since they are usually elderly and smokers, with poor nutritional status and compromised lung function. Several studies have already shown a higher risk of COVID-19 related complications in non-small cell lung cancer (NSCLC) patients, often related to their immunocompromised status (Rogado et al., 2020) . Based on these evidences, the European Society for Medical Oncology (ESMO) has also provided management and treatment recommendations for NSCLC patients adapted to the COVID-19 era (Passaro et al., 2020) . In this complex landscape, characterized by the recent occurrence of a second pandemic wave worldwide, where the emergency evolution continues to be uncertain and clinical decisions persistently difficult, sharing opinions and behaviors is of paramount importance to find new common "horizons" in the clinical management of NSCLC, and ultimately ensure, the best care to our patients. Based on these considerations, here we report the results of a national Italian survey carried out on April 2020, aiming to evaluate the clinical management of NSCLC patients and ultimately provide a reliable picture of real-word practice during the emergency of COVID-19. 

The online survey was distributed to 95 thoracic oncologists from all over Italian Regions. A total of 79 responses were received, with an overall response rate of 83%. The majority of responders (60) usually manage 

The majority of oncologists (77.3%) declared a significant change in the outpatient/day hospital management of NSCLC patients during the COVID-19 emergency (Fig.1A) . In most cases (97.5%), triage of patients, always including body temperature measurement, was regularly performed before entering the hospital and/or the Medical Oncology Unit. (Fig. 1B) . As compared to the pre-COVID-19 emergency period, the number of consultations in case of suspected NSCLC diagnosis decreased in about half of cases (46.8%), with a major reduction when considering the number of patients coming from the emergency department, as reported in about 60% of cases ( Fig. 1C and 1D ). As consequence, the total number of patients with any stage, newly diagnosed NSCLC, within the observational period, was reported to be lower than the pre-pandemic era by the 55.7% of oncologists (Fig. 1E) . Interestingly, multidisciplinary tumor boards were delayed or performed virtually in about half of cases (48.1%) (Fig. 1F ).

We asked physicians to consider their therapeutic indications for patients with stage I-III NSCLC, from the pandemic declaration to the following four weeks (March 11 th -April 11 th 2020) in comparison to the pre-COVID-19 period. As for chemotherapy administrated with adjuvant intent, clinical therapeutic indications did not change for the majority of responders (62%) ( Fig.2A) . Likewise, for the treatment of unresectable locally advanced disease, most of the Italian thoracic oncologists (72.2%) confirmed, in accordance with available guidelines, the unchanged indication to concomitant chemoradiation. However, a significant subgroup (25.3%) of colleagues declared their preference for the sequential strategy, because they consider this approach safer in terms of pulmonary toxicity (Fig. 2B ).

Physicians reported their clinical indications to the different first line treatment options during the COVID-19 pandemic. As regards chemotherapy, the majority of them (81%) declared that neither treatment recommendations were modified nor ongoing therapies were suspended. (Fig. 2C) . Similarly, clinical indications to first-line immunotherapy alone or in combination with chemotherapy remained unchanged for 78.5% and 82.3% of responders, respectively (Fig. 2D-2E) . However, the 17.7% of them declared to have delayed the beginning of immune-based treatments as far as possible (Fig. 2D-2E) . As for frontline tyrosine kinase inhibitors (TKIs), almost all responders (96.2%) confirmed that their clinical indication did not change, while only 7.6% modified the therapeutic schedule of TKI administration (Fig. 2F) . In elderly patients (over 75 years) with non-oncogene-addicted metastatic NSCLC and potentially candidate to first line therapy J o u r n a l P r e -p r o o f (chemotherapy or immunotherapy), therapeutic indications were subjected to relevant changes in the majority of cases, with about 33% of colleagues declaring a significant decrease of treatment prescription and 27.8% of them preferring alternative, less toxic schedules, or oral drugs, in order to reduce hospital accesses, and consequently risk of infection (Fig. 2G ). Maintenance therapy with pemetrexed has been regularly administered from the majority of oncologists, but free-interval between administrations has been frequently prolonged by one week (44.3% of cases) (Fig. 2H) . Similarly, as regards first-line immunotherapy, a significant percentage of oncologists declared to have prolonged the free-interval between treatment administrations (42%), to have suspended ongoing therapy in high-risk patients (19%), and to have definitively discontinued treatment in case of partial or complete response confirmed at the last computed tomography (CT) as well as in cases of long-term disease control (> 18 months of treatment) (15.2%) (Fig. 2I ).

The management of second line treatment, including either chemotherapy or immunotherapy was subjected to relevant changes for most of responders (59%), with about half of them declaring their preference for alternative schedules/drugs characterized by low toxicity profile and/or oral administration. In the remaining cases, treatment was discontinued in high-risk subgroups, like elderly or patients with multiple comorbidities.

As for second line immunotherapy, schedule of treatment has been modified or suspended in high risk patients in 27% of cases and 25% of oncologists declared to have discontinued treatment in case of partial or complete response confirmed at the last CT scan or in case of achievement of more than 18 months of treatment (Fig.2L-2M ). About 40% of oncologists declared as the tendency to discontinue any active second-line treatment in favor of best supportive care (BSC) was slightly increased during the first wave of COVID-19 pandemic (Fig.   2N ). For patients in follow up (out of any active treatment), a telemedicine approach through phone calls or emails was preferred by 78.5% of responders. Finally, as regards clinical cancer research during the COVID-19 outbreak, the majority of oncologists (79.7%) declared that the accrual of lung cancer patients within clinical trials decreased by more than 50% (Fig. 2O-2P ).

In case of suspected COVID-19 infection in NSCLC patients, in the majority of cases the nasopharyngeal swab was performed at the Emergency Department (60%), followed by the Medical Oncology Unit (39%) or general practitioners (37%) (Fig. 3A) . The majority of oncologists (73%) declared to have had less than 5 NSCLC patients or none affected by COVID-19 infection at their Institution, within the observational period (Fig. 3B) .

The characteristics of COVID-19 infection management and outcomes in NSCLC patients were reported in Table 1 .

In general, the results of this survey highlighted as both management and treatment strategies of NSCLC patients have been profoundly modified after the COVID-19 outbreak. Particularly, the reduction of the total number of novel NSCLC diagnoses, partially ascribed to the significant decrease of patients with suspected lung cancer coming from the emergency department, certainly represents one of the most relevant aspects to be adequately addressed. A recent paper, published by Dinmohamed et al, showed also a significant decrease of cancer diagnoses in the Netherlands, when compared to the pre-COVID-19 emergency period (Dinmohamed et al., 2020) . Specifically, between the 6 th of January 2019 and the 12 th of April 2020 the relative change in lung cancer diagnoses was reported to be around 30-40%. This evidence has been partially explained by the lower access of individuals with non-specific cancer symptoms to their general practitioner, leading to a subsequent delay of clinical investigations. Furthermore, several hospitals primarily involved in the COVID- 

In conclusion, this survey provides a real-word "picture" of the clinical management of NSCLC patients in Italy during first wave of COVID-19 emergency. Although the majority of Italian thoracic oncologists have proven to follow both national and international treatment guidelines even during this difficult period, however major concerns regarded the selection of second or further lines of treatment as well as the clinical management of elderly population, characterized by a potentially unfavorable risk/benefit ratio. The most relevant issues emerging from this survey included the significant delay of lung cancer diagnosis and the dramatic decrease 

Clinical Characteristics of Coronavirus Disease 2019 in China

World Health Organization. Novel coronavirus -China

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

Covid-19 and lung cancer: A greater fatality rate

ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer

Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands

Determinants of COVID-19 disease severity in patients with cancer

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines

Food and Drug Administration (FDA)

Available

Presumed asymptomatic carrier transmission of COVID-19

Speeding tumor genotyping during the SARS-CoV-2 outbreak through liquid biopsy

This research did not receive any specific grant from funding agencies in the public, commercial, or not-forprofit sectors.

Novello S declared speaker bureau/advisor's fee from Eli Lilly, MSD, Roche, BMS, Takeda, Pfizer, Astra Zeneca and Boehringer Ingelheim.Passiglia F declared consultant's fee from MSD, Boehringer Ingelheim and AstraZeneca.Bironzo P declared consultant's fee from MSD, BMS, AstraZeneca, BeiGene and Roche.Capelletto E declared consultant's fee from MSD, AstraZeneca, Boehringer Ingelheim.Other co-authors have no COI to declare.J o u r n a l P r e -p r o o f